Global Offering
578Pages

(a joint stock limited company incorporated in the People’s Republic of China with limited liability) Sole Sponsor China Everbright Capital Limited Sole Global Coordinator, Sole Bookrunner and Sole Lead Manager China Everbright Securities (HK) Limited

If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. Beijing Chunlizhengda Medical Instruments Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) GLOBAL OFFERING Number of Offer Shares under the Global Offering Number of Hong Kong Offer Shares Number of International Offer Shares Maximum Offer Price Nominal value Stock code 16,670,000 H Shares (subject to the Over-allotment Option) 1,667,000 H Shares (subject to adjustment) 15,003,000 H Shares (subject to...

EXPECTED TIMETABLE Application lists open Latest time to lodge WHITE and YELLOW Application Forms . . . . . . . . . . . . . . . . . . . . . 12:00 noon on Wednesday, 4 March 2015 Latest time to give electronic application instructions to HKSCC (iii) . . . . . . . . . . . . . . . . . . . . . . . . . 12:00 noon on Wednesday, 4 March 2015 Application lists close . . . . . . . . . . . . . . . . . . 12:00 noon on Wednesday, 4 March 2015 Expected Price Determination Date Announcement of: • the Offer Price; • the level of indications of interest in the International Offering; • the level of...

EXPECTED TIMETABLE All dates and times refer to Hong Kong local dates and times, except as otherwise stated. Details of the structure of the Global Offering, including its conditions, are set out in the section headed “Structure of the Global Offering” in this prospectus. If there is any change in this expected timetable, an announcement will be published in The Standard in English and in the Hong Kong Economic Times in Chinese and on the website of the Hong Kong Stock Exchange and our website. If there is a “black” rainstorm warning or a tropical cyclone warning signal number 8 or above in...

IMPORTANT NOTICE TO INVESTORS This prospectus is issued by us solely in connection with the Hong Kong Public Offering and the Hong Kong Offer Shares and does not constitute an offer to sell, or a solicitation of an offer to subscribe for or buy, any security other than the Hong Kong Offer Shares. This prospectus may not be used for the purpose of, and does not constitute, an offer to sell, or a solicitation of an offer to subscribe for or buy, any security in any other jurisdiction or in any other circumstances. No action has been taken to permit a public offering of the Offer Shares, or...

CONTENTS Regulatory Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Relationship with Controlling Shareholders and Directors . . . . . . . . . . . . . . . . . . Connected Transactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Share Capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Substantial Shareholders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Financial Information . ....

This summary provides an overview of the information contained in this prospectus. Because it is a summary, this section does not contain all the information that may be important to you. You should read the prospectus in its entirety, including our financial statements and the accompanying notes, before you decide to invest in the Offer Shares. There are risks associated with any investment. Some of the particular risks in investing in the Offer Shares are set out in the section headed “Risk Factors” in this prospectus. You should read this section carefully before you decide to invest in...

As at the Latest Practicable Date, we held 14 medical device registration certificates in China for the production of medical devices which cover joint prosthesis products for four major joints (namely, shoulder, elbow, hip and knee joints) and spinal products, nine of which are Class III medical device registration certificates and five of which are Class I medical device registration certificates. As at the Latest Practicable Date, the domestic joint products registration index (Bj£ iltpMS msiffl+iliir) of the CFDA showed that we were one of the medical device companies that held the most...

SUMMARY After the government authorities publicly announced the tender invitation, we or our distributors shall submit tender documents to the government authorities. Successful bidder shall enter into a written contract in accordance with the terms of the tender document. The price of orthopedic medical devices which are on the Medical Device Procurement List is affected by the tender processes. The successful bidder sell such products to the hospitals and medical institution within the region at the price offered in the bidding document. We are currently not subject to any price control...

SUMMARY In January 2011, we acquired the Tongzhou Second Production Base and the land on which it is erected adjacent to our current production site, Tongzhou First Production Base. The reason for acquiring the Tongzhou Second Production Base is two-fold. Firstly, we believed that the Tongzhou Second Production Base which is situated at the southern district of Beijing Tongzhou Economic Development Zone (the “Zone”) could cater for the needs of our business growth after taking into account numerous factors such as the anticipated high level of demand of our products in the near future, the...

SUMMARY OUR SUPPLIERS Our principal raw materials include titanium alloy, forged titanium alloy, casted Co-Cr-Mo alloy and medical-grade ultra-high molecular weight polyethylene materials. We procure all our principal raw materials from suppliers in China. For the three years ended 31 December 2013 and the nine months ended 30 September 2014, the number of suppliers of our principal raw materials were 17, 17, 21 and 23 respectively. During the same periods, the total purchases from our top five suppliers represented approximately 56.5%, 60.3%, 62.1% and 59.6% of our total purchases...